Endothelial Cell HIF-1α and HIF-2α Differentially Regulate Metastatic Success

[1]  D. Xie,et al.  MicroRNA-135a contributes to the development of portal vein tumor thrombus by promoting metastasis in hepatocellular carcinoma. , 2012, Journal of hepatology.

[2]  A. van der Vliet,et al.  Interactions between nitric oxide and hypoxia-inducible factor signaling pathways in inflammatory disease. , 2011, Nitric oxide : biology and chemistry.

[3]  D. Powe,et al.  Luminal and basal-like breast cancer cells show increased migration induced by hypoxia, mediated by an autocrine mechanism , 2011, BMC Cancer.

[4]  P. Carmeliet,et al.  From Vessel Sprouting to Normalization: Role of the Prolyl Hydroxylase Domain Protein/Hypoxia-Inducible Factor Oxygen-Sensing Machinery , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[5]  L. Coussens,et al.  Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. , 2010, Cancer research.

[6]  E. Rofstad,et al.  Tumors exposed to acute cyclic hypoxic stress show enhanced angiogenesis, perfusion and metastatic dissemination , 2010, International journal of cancer.

[7]  H. Kishimoto,et al.  Antitumor effects of inhibitors of nitric oxide synthase or cyclooxygenase-2 on human KB carcinoma cells overexpressing COX-2. , 2010, Oncology reports.

[8]  Xin Lu,et al.  In vivo dynamics and distinct functions of hypoxia in primary tumor growth and organotropic metastasis of breast cancer. , 2010, Cancer research.

[9]  M. Russo,et al.  Up‐regulation of pro‐inflammatory genes as adaptation to hypoxia in MCF‐7 cells and in human mammary invasive carcinoma microenvironment , 2010, Cancer science.

[10]  A. Hoffmann,et al.  Differential activation and antagonistic function of HIF-{alpha} isoforms in macrophages are essential for NO homeostasis. , 2010, Genes & development.

[11]  L. Ellis,et al.  VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2 , 2010, Cell Death and Differentiation.

[12]  Robert A. Harris,et al.  Loss or silencing of the PHD1 prolyl hydroxylase protects livers of mice against ischemia/reperfusion injury. , 2010, Gastroenterology.

[13]  J. Esplugues,et al.  iNOS‐derived nitric oxide mediates the increase in TFF2 expression associated with gastric damage: role of HIF‐1 , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  J. Griffin,et al.  Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion , 2009, British Journal of Cancer.

[15]  M. Ohh,et al.  Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells. , 2009, Cancer research.

[16]  L. Morbidelli,et al.  Molecular regulation of tumour angiogenesis by nitric oxide. , 2009, European cytokine network.

[17]  M. Simon,et al.  HIF-1α versus HIF-2α in endothelial cells and vascular functions: Is there a master in angiogenesis regulation? , 2009 .

[18]  B. Brüne,et al.  Nitric oxide causes macrophage migration via the HIF-1-stimulated small GTPases Cdc42 and Rac1. , 2009, Free radical biology & medicine.

[19]  V. Haase.  Oxygen regulates epithelial-to-mesenchymal transition: insights into molecular mechanisms and relevance to disease. , 2009, Kidney international.

[20]  K. Nathanson,et al.  HIF2α inhibition promotes p53 pathway activity, tumor cell death, and radiation responses , 2009, Proceedings of the National Academy of Sciences.

[21]  M. Simon,et al.  Endothelial deletion of hypoxia-inducible factor-2alpha (HIF-2alpha) alters vascular function and tumor angiogenesis. , 2009, Blood.

[22]  Frederik De Smet,et al.  Heterozygous Deficiency of PHD2 Restores Tumor Oxygenation and Inhibits Metastasis via Endothelial Normalization , 2009, Cell.

[23]  Y. Fujii‐Kuriyama,et al.  Hypoxia-inducible Transcription Factor-2α in Endothelial Cells Regulates Tumor Neovascularization through Activation of Ephrin A1* , 2008, Journal of Biological Chemistry.

[24]  John D Gordan,et al.  HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. , 2007, Cancer cell.

[25]  R. Johnson,et al.  Acute postnatal ablation of Hif-2α results in anemia , 2007, Proceedings of the National Academy of Sciences.

[26]  J. Fandrey,et al.  Nitric Oxide Modulates Oxygen Sensing by Hypoxia-inducible Factor 1-dependent Induction of Prolyl Hydroxylase 2* , 2007, Journal of Biological Chemistry.

[27]  R. Johnson,et al.  Hypoxia-Inducible Factor-1α Is a Key Regulator of Metastasis in a Transgenic Model of Cancer Initiation and Progression , 2007 .

[28]  R. Cardiff,et al.  Effects of FVB/NJ and C57Bl/6J strain backgrounds on mammary tumor phenotype in inducible nitric oxide synthase deficient mice , 2007, Transgenic Research.

[29]  J. Massagué,et al.  Cancer Metastasis: Building a Framework , 2006, Cell.

[30]  Å. Borg,et al.  Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. , 2006, Cancer cell.

[31]  J. Erler,et al.  Lysyl oxidase mediates hypoxic control of metastasis. , 2006, Cancer research.

[32]  V. Haase.  Hypoxia-inducible factors in the kidney. , 2006, American journal of physiology. Renal physiology.

[33]  R. Jain,et al.  The role of nitric oxide in tumour progression , 2006, Nature Reviews Cancer.

[34]  H. Wall,et al.  Monomelic Spread of Metastatic Disease due to Proximal Deep Venous Thrombosis , 2006 .

[35]  E. Hatano,et al.  Complete response by a combination of 5-fluorouracil and interferon-alpha chemotherapy for lung metastasis of hepatocellular carcinoma after hepatic resection with portal and hepatic vein tumor thrombectomy. , 2005, Hepatology research : the official journal of the Japan Society of Hepatology.

[36]  D. Heistad,et al.  Mechanisms of Inducible Nitric Oxide Synthase–Mediated Vascular Dysfunction , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[37]  L. Gunaratnam,et al.  Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer. , 2005, Cancer research.

[38]  Nan Tang,et al.  Loss of HIF-1α in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis , 2004 .

[39]  D. Cheresh,et al.  Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis , 2004, The Journal of cell biology.

[40]  Jeffrey W Pollard,et al.  Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. , 2003, The American journal of pathology.

[41]  I. Macdonald,et al.  Metastasis: Dissemination and growth of cancer cells in metastatic sites , 2002, Nature Reviews Cancer.

[42]  D. Pinsky,et al.  Endothelial response to hypoxia: physiologic adaptation and pathologic dysfunction , 2002, Current opinion in critical care.

[43]  Mirna Lechpammer,et al.  Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. , 2002, Cancer cell.

[44]  Rainer Constien,et al.  Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line , 2001, Genesis.

[45]  X. Le,et al.  Genetic disruption of host nitric oxide synthase II gene impairs melanoma‐induced angiogenesis and suppresses pleural effusion , 2001, International journal of cancer.

[46]  R K Jain,et al.  Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[47]  R. Hammer,et al.  Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo. , 2001, Developmental biology.

[48]  J. M. Arbeit,et al.  Hypoxia-inducible Factor-1α Is a Positive Factor in Solid Tumor Growth , 2000 .

[49]  D A Hilton,et al.  Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. , 1999, Cancer research.

[50]  T. Danielsen,et al.  Hypoxia-induced metastasis of human melanoma cells: involvement of vascular endothelial growth factor-mediated angiogenesis , 1999, British Journal of Cancer.

[51]  M Aguet,et al.  VEGF is required for growth and survival in neonatal mice. , 1999, Development.

[52]  D. Hedley,et al.  Heterogeneity of tumor oxygenation: relationship to tumor necrosis, tumor size, and metastasis. , 1998, International journal of radiation oncology, biology, physics.

[53]  Jessica Lo,et al.  HIF‐1α is required for solid tumor formation and embryonic vascularization , 1998 .

[54]  C. Harris,et al.  Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. , 1998, Cancer research.

[55]  C. Garlanda,et al.  A general strategy for isolation of endothelial cells from murine tissues. Characterization of two endothelial cell lines from the murine lung and subcutaneous sponge implants. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[56]  Richard Graham Knowles,et al.  Selective inhibition of inducible nitric oxide synthase inhibits tumor growth in vivo: studies with 1400W, a novel inhibitor. , 1997, Cancer research.

[57]  G. Melillo,et al.  Functional Requirement of the Hypoxia-responsive Element in the Activation of the Inducible Nitric Oxide Synthase Promoter by the Iron Chelator Desferrioxamine* , 1997, The Journal of Biological Chemistry.

[58]  M. Dewhirst,et al.  Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. , 1996, Cancer research.

[59]  A. Sica,et al.  A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter , 1995, The Journal of experimental medicine.

[60]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[61]  L. Ignarro,et al.  Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[62]  S. Moncada,et al.  Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor , 1987, Nature.

[63]  L. Ostrowski,et al.  Selective inhibition of proteolytic enzymes in an in vivo mouse model for experimental metastasis. , 1986, Cancer research.

[64]  T. Sugimura,et al.  Inhibition of experimental blood-borne lung metastasis by protease inhibitors. , 1980, Cancer research.

[65]  S. Mousa,et al.  Assessment of anti-metastatic effects of anticoagulant and antiplatelet agents using animal models of experimental lung metastasis. , 2010, Methods in molecular biology.

[66]  M. Simon,et al.  HIF-1alpha versus HIF-2alpha in endothelial cells and vascular functions: is there a master in angiogenesis regulation? , 2009, Cell Cycle.

[67]  R. Johnson,et al.  Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. , 2007, Cancer research.

[68]  R. Johnson,et al.  Acute postnatal ablation of Hif-2alpha results in anemia. , 2007, Proceedings of the National Academy of Sciences of the United States of America.

[69]  H. Van der Wall,et al.  On the AJR viewbox. Monomelic spread of metastatic disease due to proximal deep venous thrombosis. , 2006, AJR. American journal of roentgenology.

[70]  A. Aggarwal,et al.  On the AJR Viewbox , 2006 .

[71]  J. Degen,et al.  Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. , 2005, Blood.

[72]  J. Huber,et al.  Nitric oxide mediates hypoxia-induced changes in paracellular permeability of cerebral microvasculature. , 2004, American journal of physiology. Heart and circulatory physiology.

[73]  J. M. Arbeit,et al.  Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. , 2000, Cancer research.

[74]  H. Ryan,et al.  HIF-1 alpha is required for solid tumor formation and embryonic vascularization. , 1998, The EMBO journal.

[75]  N. Svanvik,et al.  interactions between , 1998 .

[76]  E. Manseau,et al.  Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. , 1996, Cancer research.

[77]  C. Grossi,et al.  The rationale of anticoagulants in the treatment of cancer. , 1974, Journal of medicine.

[78]  Cliffton Ee,et al.  The rationale of anticoagulants in the treatment of cancer. , 1974 .